Last reviewed · How we verify
Dexamethasone. Dart
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Inflammatory and immune-mediated conditions (pediatric use), Cerebral edema, Acute respiratory distress syndrome (ARDS).
At a glance
| Generic name | Dexamethasone. Dart |
|---|---|
| Sponsor | The Children's Hospital of Zhejiang University School of Medicine |
| Drug class | Glucocorticoid (corticosteroid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Inflammation |
| Phase | Phase 3 |
Mechanism of action
Dexamethasone acts as a potent corticosteroid that inhibits phospholipase A2, reducing prostaglandin and leukotriene production, and suppresses T-cell and B-cell proliferation. It decreases inflammatory cytokine production and increases anti-inflammatory mediators, making it effective for reducing inflammation and immune-mediated responses across multiple organ systems.
Approved indications
- Inflammatory and immune-mediated conditions (pediatric use)
- Cerebral edema
- Acute respiratory distress syndrome (ARDS)
Common side effects
- Hyperglycemia
- Immunosuppression / increased infection risk
- Hypertension
- Insomnia
- Mood changes
- Osteoporosis (with chronic use)
Key clinical trials
- Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies (PHASE1)
- Dexamethasone Regimens for BPD Prevention in Preterm Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: